WO2014195810A3 - Compositions and methods for the treatment of diabetes and pre-diabetes - Google Patents

Compositions and methods for the treatment of diabetes and pre-diabetes Download PDF

Info

Publication number
WO2014195810A3
WO2014195810A3 PCT/IB2014/058634 IB2014058634W WO2014195810A3 WO 2014195810 A3 WO2014195810 A3 WO 2014195810A3 IB 2014058634 W IB2014058634 W IB 2014058634W WO 2014195810 A3 WO2014195810 A3 WO 2014195810A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
compositions
treatment
methods
pharmaceutical
Prior art date
Application number
PCT/IB2014/058634
Other languages
French (fr)
Other versions
WO2014195810A2 (en
Inventor
Mahesh Kandula
Original Assignee
Cellixbio Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2013/059680 external-priority patent/WO2014080307A2/en
Application filed by Cellixbio Private Limited filed Critical Cellixbio Private Limited
Priority to CA2914461A priority Critical patent/CA2914461A1/en
Priority to AU2014276346A priority patent/AU2014276346A1/en
Priority to EP14725542.6A priority patent/EP3004049B1/en
Priority to SG11201509782TA priority patent/SG11201509782TA/en
Priority to PCT/IN2014/000089 priority patent/WO2014195961A1/en
Priority to US14/244,911 priority patent/US8952068B2/en
Publication of WO2014195810A2 publication Critical patent/WO2014195810A2/en
Priority to US14/583,117 priority patent/US9174931B2/en
Publication of WO2014195810A3 publication Critical patent/WO2014195810A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3

Abstract

The invention relates to the compositions of formula I or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of metformin and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.
PCT/IB2014/058634 2013-06-04 2014-01-29 Compositions and methods for the treatment of diabetes and pre-diabetes WO2014195810A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2914461A CA2914461A1 (en) 2013-06-04 2014-02-12 Compositions and methods for the treatment of diabetes and pre-diabetes
AU2014276346A AU2014276346A1 (en) 2013-06-04 2014-02-12 Compositions and methods for the treatment of diabetes and pre-diabetes
EP14725542.6A EP3004049B1 (en) 2013-06-04 2014-02-12 Compositions and methods for the treatment of diabetes and pre-diabetes
SG11201509782TA SG11201509782TA (en) 2013-06-04 2014-02-12 Compositions and methods for the treatment of diabetes and pre-diabetes
PCT/IN2014/000089 WO2014195961A1 (en) 2013-06-04 2014-02-12 Compositions and methods for the treatment of diabetes and pre-diabetes
US14/244,911 US8952068B2 (en) 2013-06-04 2014-04-04 Compositions for the treatment of diabetes and pre-diabetes
US14/583,117 US9174931B2 (en) 2013-06-04 2014-12-25 Compositions for the treatment of diabetes and pre-diabetes

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
IN2448CH2013 2013-06-04
IN2448/CHE/2013 2013-06-04
PCT/IB2013/059680 WO2014080307A2 (en) 2012-11-21 2013-10-26 Compositions and methods for the treatment of diabetes and pre-diabetes
IBPCT/IB2013/059680 2013-10-26
IN5592CH2013 2013-12-04
IN5592/CHE/2013 2013-12-04
IN315CH2014 2014-01-25
IN315/CHE/2014 2014-01-25

Publications (2)

Publication Number Publication Date
WO2014195810A2 WO2014195810A2 (en) 2014-12-11
WO2014195810A3 true WO2014195810A3 (en) 2017-03-09

Family

ID=52008658

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/058634 WO2014195810A2 (en) 2013-06-04 2014-01-29 Compositions and methods for the treatment of diabetes and pre-diabetes

Country Status (1)

Country Link
WO (1) WO2014195810A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015022613A1 (en) * 2013-08-11 2015-02-19 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
CN107108471B (en) * 2015-01-19 2019-08-30 昭和电工株式会社 Compound, the salt of compound, skin preparations for extenal use, cosmetic preparation and food additives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106688A1 (en) * 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
US20120178813A1 (en) * 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106688A1 (en) * 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
US20120178813A1 (en) * 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent

Also Published As

Publication number Publication date
WO2014195810A2 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
WO2014087307A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2013175377A3 (en) Compositions and methods for treatment of mucositis
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
MX2019007713A (en) Compositions and methods for the treatment of chronic pain.
WO2014174425A3 (en) Compositions and methods for the treatment of orthostasis and neurological diseases
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
WO2014080307A3 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
WO2014106804A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2014195810A3 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
WO2014091384A3 (en) Compositions and methods for the treatment of mucositis
MX2019006163A (en) Compositions and methods for the treatment of oral infectious diseases.
WO2013167998A3 (en) Compositions and methods for the treatment of autonomic and other neurological disorders
WO2014087323A3 (en) Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases
WO2015015403A3 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
WO2014195850A3 (en) Compositions and methods for the treatment of neurologic diseases and neurological disorders
MX2019005568A (en) Compositions and methods for the treatment of gastrointestinal polyps.
WO2013175344A3 (en) Compositions and methods for treatment of peridontitis and rheumatoid arthritis
WO2014097137A3 (en) Compositions and methods for the treatment of seizures and neurologic diseases
WO2013167995A3 (en) Compositions and methods for the treatment of hyperglycemia
WO2014106805A3 (en) Fatty acid conjugates and their uses
WO2015028976A3 (en) Compounds and methods for the treatment of inflammatory diseases
WO2014083476A3 (en) Compositions and methods for the treatment of metabolic and lipid disorders

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14808289

Country of ref document: EP

Kind code of ref document: A2